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Background: Extra-oesophageal reﬂux (EOR) may lead to microaspiration in patients with cystic ﬁbrosis (CF), a probable cause of deteriorating
lung function. Successful clinical trials of ivacaftor highlight opportunities to understand EOR in a real world study.
Methods: Data from 12 patients with CF and the G551D mutation prescribed ivacaftor (150 mg bd) was collected at baseline, 6, 26 and 52 weeks.
The changes in symptoms of EOR were assessed by questionnaire (reﬂux symptom index (RSI) and Hull airway reﬂux questionnaire (HARQ)).
Results: Six patients presented EOR at baseline (RSI N13; median 13; range 2–29) and 5 presented airway reﬂux (HARQ N13; median 12; range 3
to 33). Treatment with ivacaftor was associated with a signiﬁcant reduction of EOR symptoms (P b 0 ∙04 versus baseline) denoted by the reﬂux
symptom index and Hull airway reﬂux questionnaire.
Conclusion: Ivacaftor treatment was beneﬁcial for patients with symptoms of EOR, thought to be a precursor to microaspiration.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Keywords: G551D; CFTR potentiator; Gastrointestinal; Real life data1. Introduction
Cystic fibrosis (CF) is a genetic condition caused by
abnormalities in the CF transmembrane conductance regulator
(CFTR) gene. Patients with CF experience life-long morbidityuthor at: Institute for Cellular Medicine, Medical School,
ty, Catherine Cookson Building, Framlington Place,
e NE2 4HH, United Kingdom. Tel.: +44 191 2228460.
Chris.Ward@newcastle.ac.uk (C. Ward).N
N016/j.jcf.2016.07.004
he Authors. Published by Elsevier B.V. on behalf of European
ons.org/licenses/by/4.0/).and premature mortality, associated with lung disease. The
exact pathophysiology of CF remains an area of much interest
and research. It is recognised as a multi-system disorder
involving the respiratory and gastrointestinal tract [1–3].
Gastrointestinal problems constitute a significant consideration
in patients with CF. Extra-oesophageal reflux (EOR) is known
to occur frequently in the adult CF population, the prevalence
ranges from 55 to 90% in different studies [4]. EOR is the
retrograde movement of reflux which leaves the oesophagus,
leading to symptoms such as cough, hoarseness, post-nasal dripCystic Fibrosis Society. This is an open access article under the CC BY license
Table 1
Demographics and characteristics of subjects at baseline. Note: FEV1 forced
expiratory volume in 1 s; FVC forced vital capacity; PS pancreatic sufficiency;
PPI Proton Pump Inhibitor; H2RA Histamine 2 receptor agonist; – no PPI or
H2RA; NMD no mutation detected.
Subject Sex Age (years) PS
Acid
suppression Genotype
1 F 20 Yes PPI G551D/P67L
2 M 22 No PPI G551D/F508del
3 F 21 No – G551D/G542X
4 F 21 No – G551D/F508del
5 F 17 No PPI G551D/F508del
6 F 38 No H2RA G551D/F508del
7 F 20 No PPI G551D/F508del
8 M 23 No PPI G551D/F508del
9 M 25 No H2RA G551D/F508del
10 M 28 No PPI G551D/F508del
11 M 24 No PPI G551D/F508del
12 M 28 No – G551D/W401X
Median
(range)
24
17–38
125G.L. Zeybel et al. / Journal of Cystic Fibrosis 16 (2017) 124–131and globus [10]. Reflux-induced cough and reported EOR
symptoms have been associated with reduced lung function [4].
In pilot work we detected bile acids in the lower airways of 9
patients homozygous for F508del with advanced CF lung
disease at the time of lung transplantation [5], and this potential
source of injury persisted after lung transplantation [6]. This
indicated that microaspiration of refluxate in patients with CF
might be a mechanism of injury linking gastrointestinal prob-
lems with lung disease [7].
The clinical success associated with trials of the CFTR
potentiator ivacaftor (Vertex Pharmaceuticals, Massachusetts,
USA) in patients with CF and the G551D mutation [8] high-
lights an opportunity for pragmatic studies to understand
clinically relevant CF pathophysiology and symptoms [2]. It is
recognised that apart from formal trial populations, data from
clinical populations, gained in the post-approval era of ivacaftor
is highly valued [2,9]. Rowe and colleagues provided an
excellent review of the North American experience of ivacaftor
treatment in patients with CF and the G551D mutation [3].
They confirmed previous data observing gains in lung function
after 1 month of ivacaftor treatment and weight gain accom-
panied by body mass index (BMI) after 6 months of treatment.
In particular, a sub-study of seven patients underwent post-
prandial intestinal pH measurements to investigate the role of
ivacaftor within intestinal pH profiles. Following 1 month of
ivacaftor treatment, a significant improvement was observed in
the early ability to promote postprandial duodenal neutralisa-
tion when compared to baseline measurements. The observed
improvement of weight gain, occurring with ivacaftor treat-
ment, along with the four week longitudinal intestinal pH data
highlights a potentially central role for CFTR in gastrointestinal
complications modified by this new approach to therapy [3].
With longitudinal gastrointestinal data rare in the specialised
setting of ivacaftor treatment, and absent beyond the four week
time point, we performed an uncontrolled, observational study
of twelve patients with CF with one copy of the G551D CFTR
mutation. Patients were treated with ivacaftor for 12 months.
We evaluated validated questionnaire based instruments of
EOR, selected prospectively following a formal literature re-
view and hypothesised that clinical improvements in lung
function associated with ivacaftor therapy would be associated
with a positive and sustained impact on symptoms of reflux.
2. Methods
Ethical approval was granted by County Durham & Tees
Valley 2 Research Ethics Committee (REC NO: 10/H0908/8). The
ethics complied with the principles laid down in the Declaration of
Helsinki. Clinic patients receiving ivacaftor (150 mg bd) for the
first time were invited to take part in this study.
A total of twelve patients with one copy of the G551D CFTR
mutation were recruited (six female, median age 24 years,
Table 1) to the study from the Regional Adult CF Service,
Royal Victoria Infirmary, Newcastle upon Tyne. We obtained
written informed consent from each patient during recruitment.
Following directions from the NHS guidelines, sweat chlo-
ride levels were assessed at baseline to assess eligibility for thetreatment programme (a baseline sweat chloride concentration of
N60 mmol/L was required for treatment to observe a N30% fall
following ivacaftor). Seven patients were prescribed a Proton
Pump Inhibitor (PPI) and one Histamine2-Receptor Agonist
(H2RA) prior to starting ivacaftor. There were six patients
prescribed with azithromycin, two patients were taking a 250 mg
dose every day and four patients were taking 500 mg three times
per week. Of the total number of patients, 11 were pancreatic
insufficient and thus prescribed pancreatic enzyme replacement
therapy (PERT) (CREON® range 2500 to 7700 units/kg/day).
These medications continued throughout the study.
Validated questionnaires designed to assess the symptoms of
extra-oesophageal reflux disease were selected following a formal
review of the literature (RJ, MM, GZ). This led us to a prospective
decision to adopt the Hull airway reflux questionnaire (HARQ)
and reflux symptom index (RSI) score. These questionnaires have
previously been validated against gold standard pH impedance
measurements. In brief, the RSI is a patient reported outcome
measure designed to assess laryngeal symptoms secondary to
reflux. [10] The HARQ was designed by respiratory physicians to
assess the impact of reflux on the airways and was validated
amongst 185 patients and 70 volunteers [11]. The two validated
reflux questionnaires were completed by the patients, on initial
assessment for receiving ivacaftor (baseline), six, 26 and 52 weeks
after first taking the medication. The RSI questionnaire assessed
EOR symptoms (max score 45, score b12 classed as not EOR
symptomatic) [10]. The HARQ was used to assess cough related
EOR (max score 70, score b12 classed as not being cough related
EOR symptomatic) [11].
Measurements of sweat chloride (mmol/L), weight (kg), and
pulmonary function (forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) percentage of predicted) were collected
to assess clinical efficiency in line with the North of England
specialised Commissioning Group and the NHS commissioning
policy (NHSCB/A01/P/b). These parameters were recorded at
baseline, six, 26, and except for sweat chloride, 52 weeks. The
Fig. 1. Median scores of extra-oesophageal reflux symptom severity from baseline to 52 weeks with ivacaftor treatment (150 mg bd) at 6, 26, and 52 weeks
*P b 0.05. (A) The reflux symptom index score at baseline was 13 (range 2 to 29). It reduced to a median score of 7 at 6 weeks (range 0 to 23; P = 0.0054); 4 at
26 weeks (range 1 to 16; P = 0.0054) and 2 at 52 weeks (range 0 to 16; P = 0.02). (B) The Hull airway reflux questionnaire score at baseline was 12 (range 3 to 33).
It reduced to a median score of 8 (range 1 to 27; P = 0.02) at 6 weeks; 6 (range 1 to 24; P = 0.01) at 26 weeks and 3 at 52 weeks (range 0 to 16; P = 0.04). (C) Five
patients were EOR symptomatic determined by the reflux symptom index score (RSI N13) on PPI/H2RA at baseline. Of these patients, 4 became free of symptoms at
during the remainder of the study. (D) EOR/cough determined by the Hull airway reflux questionnaire (HARQ N13) identified 4 symptomatic patients at baseline on
PPI/H2RA. This reduced to 2 symptomatic patients during the remainder of the study. Note: bd twice daily; PPI proton pump inhibitors; H2RA Histamine2 receptor
agonists; EOR extra-oesophageal reflux.
126 G.L. Zeybel et al. / Journal of Cystic Fibrosis 16 (2017) 124–131predicted values for pulmonary function measurements were
corrected according to age, gender, and height reference ranges
using European standard reference equations [12].
GraphPad Prism version six (GraphPad Software Inc., La
Jolla, California, USA) and MiniTab version 16 (MiniTab Inc.,
State College, PA, USA) were used for statistical analysis. We
performed nonparametric tests due to the small number of
patients, these tests do not assume any distribution for the data,
which are expressed as median and range. The one-sample
Wilcoxon signed rank test was performed on all 12 patients to
compare the median difference of each follow-up group. TheFig. 2. (A) median baseline percentage of predicted FEV1 was 79% (range 19 to 11
93% (range 32 to 124; P = 0.001) at 26 weeks; 91 (range 32 to 115; P = 0.005) at 52
119). Increasing to 100% (range 60 to 125; P = 0.0005) at 6 weeks; 100% (range
52 weeks. (C) Comparison of FEV1 % predicted and the presence of extra-oesopha
over a time frame of 52-week treatment with ivacaftor (150 mg bd) at a follow-up pe
a lower FEV1 predicted at baseline (reflux symptom index median 50%; range 19 to 9
symptoms (reflux symptom index median 89%; range 64 to 110; Hull airway reflux
expiratory volume in 1 s); FVC (Forced vital capacity). RSI reflux symptom index;Mann–Whitney test was used to compare unpaired data. The
Friedman test was used for one-way repeated measures
analysis. Conventional levels of statistical significance testing
were used with P ≤ 0.05 considered significant.
3. Results
Data was available from 12 patients at baseline, and fol-
lowing six, 26, and 52 weeks of ivacaftor treatment. The reflux
questionnaire data was missing for one patient at 52 weeks due
to the patient relocating to another country.0). Increasing from baseline to 101% (range 35 to 132; P = 0.0005) at 6 weeks;
weeks. (B) Median baseline percentage predicted of FVC was 89% (range 35 to
53 to 124; P = 0.0005) at 26 weeks and 100% (range 54 to 116; P = 0.05) at
geal reflux (EOR) symptoms at baseline. Lung function analysed from baseline
riod of 6, 26 weeks and 52 weeks. (A) Patients who were EOR symptomatic had
0; Hull airway reflux median 35%; range 19 to 87) compared to patients with no
median 90%; range 64 to 110; P = 0.01). Note: bd (twice daily); FEV1 (forced
HARQ Hull airway reflux questionnaire; EOR extra-oesophageal reflux.
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For the patient group as a whole (n = 12), the median RSI
score at baseline was 13 (range 2 to 29). There was a significant
decrease in EOR symptoms at the 6 weeks (median 7; range 0
to 23; p = 0.005 versus baseline), 26 weeks (median 4; range 1
to 16; P = 0.005 versus baseline) and 52 weeks (n = 11;
median 2; range 0 to 16; P = 0.02) follow-up (Friedman test
n = 11 P = 0.03). EOR symptoms were present in six patients
at baseline (RSI score N13). Four of these patients became
non-symptomatic (RSI score b12) throughout the treatment of
ivacaftor (Fig. 1A).
Of the total 12 patients, the median HARQ score at baseline
was 12 (range 3 to 33). There was a significant decrease in cough
related EOR at 6 weeks (median 8; range 1 to 27; P = 0.003
versus baseline), 26 weeks (median 6; range 1 to 24; P = 0⋅01
versus baseline) and 52 weeks (n = 11; median 3; range 0 to 16;
P = 0⋅04 versus baseline) follow-up. Five patients were positive
for cough related EOR symptoms at baseline (HARQ score N13)
(Friedman test n = 11 P = 0.006). During ivacaftor treatment the
number of symptomatic patients decreased to three patients at
6 weeks, four patients after 26 weeks and three patients after
52 weeks (Fig. 1B).3.2. Symptoms of reflux in patients on PPI medication
Of the total 12 patients, 9 were treated with acid suppressive
therapy. Symptoms of EOR remained in those patients treated
with PPI therapy and H2RA's at baseline. Five of these patients
were symptomatic determined by the RSI at baseline, with 4
determined by the HARQ at baseline. Symptom severity
decreased in all these patients during ivacaftor treatment.
There were four patients with an RSI score below 12 and 2 with
a HARQ score below 12, classified as non-symptomatic at the
6 week, 26 week and 52 week follow-up. There were no
discernible differences in the effect of ivacaftor treatment
associated with reflux medication (Fig. 1C and D).3.3. Lung function
For the whole study group, the median FEV1 predicted
significantly increased from 79% (range 19 to 110) at baseline to
101% (range 35 to 132) at the six week follow-up (P = 0⋅0005
versus baseline). The FEV1 predicted remained significantly
increased from baseline at 93% (range 32 to 124) during the
26 week follow-up (P = 0⋅001 versus baseline) and 91% (range
32 to 115) during the 52 week follow-up (P = 0.005 versus
baseline) (Friedman test n = 12 P = 0.0003) (Fig. 2A).
The median FVC % predicted was 89% at baseline (range 35
to 119). The FVC % predicted significantly increased to a
median of 100% (range 60 to 125; P = 0 ⋅0005 versus baseline)
at the six week follow-up, 100% (range 53 to 124; P = 0 ⋅0005
versus baseline) at 26 weeks and to 100% (range 54 to 116;
P = 0⋅05 versus baseline) at 52 weeks. (Friedman test n = 12,
P = 0.0003) (Fig. 2 B).3.4. Lung function and symptoms of EOR at baseline
Of the total 12 patients, the median FEV1 predicted was
79% (range 19 to 110) at baseline (Fig. 2B). At this time, the
median lung function of EOR symptomatic patients determined
by the RSI was 50% (range 19 and 90) and 35% determined by
the HARQ (range 19 to 87). The median FEV1 predicted of the
group of patients who did not present EOR symptoms at
baseline was significantly higher when compared to the EOR
symptomatic group (89% denoted by the RSI; range 64 to 110
and 90% denoted by the HARQ; range 64 to 110; P = 0 ∙01)
(Fig. 2C).
3.5. Sweat chloride
The median sweat chloride concentration was 109 mmol/L
(range 61 to 131) at baseline. The median significantly decreased
to 51 mmol/L (range 27 to 94) at the six week follow-up (P =
0 ∙0005 versus baseline), the median change was −55 mmol/L
(range −72 to −31). There were two patients with a sweat chloride
concentration falling below 39 mmol/L at the six week follow-up,
into the normal range. The concentrations remained significantly
decreased following 26 weeks of treatment at a median of
45 mmol/L (range 20 to 91; P b 0 ∙0005 versus baseline), the
median change was −56 (range −77 to −40). There were six
patients with normal sweat chloride concentrations 26 weeks post
ivacaftor. (Friedman test n = 12 P = b0.0001) (Fig. 3A).
3.6. Weight
The median weight at baseline was 64 kg (range 41 to 83).
After 6 weeks of treatment, the median weight was 63 kg
(range 41 to 87). The median weight increased significantly at
the 26 week follow-up by 3 kg (range −1 to 13) from baseline,
to a median of 66 kg (range 43 to 92; P = 0 ∙001 versus
baseline). The weight remained significantly increased by 2 kg
(range −2 to 11) from baseline, to a median of 65 kg (range 41
to 90; P = 0 ∙01 versus baseline) at 52 weeks (Friedman test
n = 12 P = b0.02) (Fig. 3B).
4. Discussion
In this study we have shown that patients with CF and the
G551D mutation undergoing treatment with ivacaftor experience
a significant decline in symptoms of EOR. We also provided rare
longitudinal data in a clinical, non-trial cohort, showing that
ivacaftor treatment was associated with rapid changes in sweat
chloride and clinically significant gains in lung function, as
documented in clinical trials [8]. Significant weight gain was also
seen following prolonged treatment of ivacaftor in our patient
cohort. Interestingly, a small fall in measures of lung function and
weight was seen 52 weeks, compared to 6 and 26 weeks. Such
variation may be typical of real world data, and patients will often
show some fluctuation of measurements in a complex clinical
disease and longer term follow-up is warranted.
It is evident that ivacaftor treatment represents an opportu-
nity to investigate clinically relevant aspects of CF
Fig. 3. The clinical parameters analysed from baseline over a time frame of 52 weeks treatment with ivacaftor (150 mg bd) at a follow-up period of 6, 26 weeks and
(omitting sweat chloride) 52 weeks. *P ≤ 0 ∙05. (A) The median sweat chloride (mmol/L) at baseline was 109 mmol/L (range 61 to 131). The absolute change was
−55 at 6 weeks (range −72 to −31; P = 0.0001) and −56 at 26 weeks (range −77 to −40; P = 0.0001). (B) The baseline median weight (kg) was 64 kg (range 41 to
83), 63 kg at 6 weeks (range 41 to 87); increasing to 66 kg at 26 weeks (range 43 to 92; P = 0.001 versus baseline) and 65 kg at 52 weeks (range 41 to 90; P = 0.01
versus baseline).
129G.L. Zeybel et al. / Journal of Cystic Fibrosis 16 (2017) 124–131pathophysiology in a patient setting characterised by increased
CFTR function [2–9]. Recent decades have seen improved
success in managing patients with CF, with an increased life
expectancy. We expect that knowledge regarding CF
co-morbidities aside from pulmonary manifestations, is likely
to become increasingly important [2].
Gastro-oesophageal reflux is a recognised co-morbidity in CF
and occurs in up to 90% of patients [4]. We have previously
shown that reflux and aspiration can be an important injury in
patients with CF both in end stage disease [5] and following lung
transplantation [13,14]. It is therefore possible that reflux and
aspiration could be a significant, chronic, and persistent con-
tributor to CF pathophysiology [5,7,13–15]. It was of interest
that patients who were experiencing symptoms of reflux in our
study had worse lung function than those with lower levels of
symptoms. We found that ivacaftor was beneficial for patientswith symptoms of EOR, which is thought to be a precursor to
microaspiration. Our findings may therefore be important both in
terms of managing gastrointestinal symptoms associated with CF
per se but also because reflux and aspiration may contribute to
chronic lung disease in CF.
Evidence provided by a recent longitudinal cohort study
involving the North American Cystic Fibrosis Therapeutics
Development Network indicates a role of CFTR in gastroin-
testinal physiology following ivacaftor treatment [3]. The
authors suggested that their observations provided “seminal
information” regarding a possible mechanism underlying the
clinical benefits of gastrointestinal disease following ivacaftor
such as observed weight gain. A total of seven patients pre-
scribed ivacaftor (150 mg bd) were obtained from three centres
yielding telemetric data monitoring postprandial intestinal pH.
The authors found that the duodenal pH levels of CF patients
130 G.L. Zeybel et al. / Journal of Cystic Fibrosis 16 (2017) 124–131observed after 1 month of ivacaftor treatment were comparable
to those seen in normal individuals [3]. In normal individuals,
the pH of the intestines following gastric emptying is 7.0 to 8.5.
This indicated that after 1 month of ivacaftor treatment there
was a pronounced effect on duodenal alkalization after gastric
emptying, attributed to CFTR potentiation. The novelty of
such data was identified in an accompanying editorial which
encouraged further study [2]. To our knowledge, the effects of
ivacaftor on EOR symptoms have not been investigated and we
feel that our study therefore supports and complements the
findings of Rowe et al. [3] providing data from a European
patient setting, with longer term follow-up of 52 weeks, and in
a larger group of patients.
Our finding, that patients treated with PPIs were symptom-
atic for EOR prior to ivacaftor was of interest to us. As reflected
in our data there is frequent administration of PPI's in patients
with CF. This is due to the fact the prevalence of reflux is high,
and to optimise the effectiveness of PERT in CF. The use of
PPIs has recently been associated with a dysregulated gastric
microbiome in paediatric studies and links suggested between
reflux, aspiration and the lung microbiome [16,17]. Our data
could be consistent with a situation where PPI usage does not
prevent EOR but may also be associated with abnormal
bacterial growth in the stomach with iatrogenic potential. We
suggest that further research is indicated in this regard, which
may be especially relevant in CF.
Our study has limitations including its observational nature
and lack of placebo control. Arguably, our patient reported
outcomes may be biased by non-specific treatment benefit such
as effects of improved lung function. A strength of our study is
that it provides new information about reflux in CF in a very
rare setting. We recruited 5% of the CF population attending
the Regional CF clinic in Newcastle upon Tyne, this percentage
reflects the G551D population in the United Kingdom [18],
however a larger group would have increased statistical power.
Furthermore, our study provided an extended longitudinal
follow-up of 12 months. The collection of data within a real
world setting has been advocated [2,19] to complement the
evidence base from high quality clinical trials [8]. This small
study provides initial real world data which might prompt
further research which might include invasive physiological
testing such as pH impedance studies. We would suggest that
future studies include biomarker and physiological end points,
integrated with patient reported outcomes. Such studies may
provide increased insights into a multi-system pathophysiology
and potential therapeutic approaches, in an exciting new era of
precision medicine in CF.
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